You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK)與Madrigal達成20.75億美元重磅合作,創新藥出海再突破
格隆匯 07-30 17:03

格隆匯7月30日丨石藥集團(01093.HK)發佈公吿,集團已與Madrigal Pharmaceuticals, Inc.(“Madrigal”)就集團的口服小分子激活胰高血糖素樣肽-1(“GLP-1”)受體激動劑SYH2086在全球的開發、生產及商業化訂立獨家授權協議。

根據該協議的條款,集團同意授予Madrigal在全球範圍內開發、生產及商業化SYH2086的獨家授權,同時保留集團在中國開發和銷售其他口服小分子GLP-1受體激動劑產品的權益。集團有權收取最高可達20.75億美元的總代價,包括1.2億美元的預付款、最高可達19.55億美元的潛在開發、監管及商業里程碑付款,以及基於SYH2086年度淨銷售額的高達雙位數銷售提成。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account